Axon Enterprise (AXON -4.18%) works to improve the efficiency of public safety services.
Tariffs and the potential for trade wars are currently affecting the global economy and causing concern in the markets. Many investors are worried about how long this situation will continue and how badly it could harm businesses. This uncertainty is making some investors anxious.
On March 7, 2025, Axon Enterprise, Inc. (Nasdaq: AXON) announced that it has made private exchange agreements with some holders of its 0.50% convertible senior notes that are due in 2027.
On March 5, 2025, Axon (Nasdaq: AXON) announced that it has set the price for $1 billion in Senior Notes due in 2030 and $750 million in Senior Notes due in 2033, both at an issue price of 100%. This private offering is exempt from the registration rules of the Securities Act of 1933. The two sets of notes are referred to as the "Notes."
On March 5, 2025, Axon Enterprise, Inc. (Nasdaq: AXON) announced its plan to offer $1.5 billion in senior notes, which will include notes due in 2030 and 2033. This private offering will be exempt from the registration requirements of the Securities Act of 1933, subject to market conditions.
Axon (AXON 0.57%) has been experiencing significant growth, and this trend has carried on into 2024. In this video, Travis Hoium discusses the reasons behind Axon's increasing revenue and the expanding market opportunities.
AXON is making progress in important markets, which means the stock is worth keeping an eye on despite some challenges.
Axon Enterprise, an industrials company listed on NASDAQ as AXON, had a strong beginning in 2025, but things changed recently. The stock price fell significantly for four consecutive trading days from February 19 to 24.
Trevor Walsh, an analyst at Citizens Capital Markets, has maintained a Market Outperform rating for Axon Enterprise Inc (AXON) and set a price target of $725.
The Nasdaq Composite dropped 5% from its peak last week due to concerning economic information, such as the lowest consumer sentiment in 15 months. Lee Simpson from Morgan Stanley has given Arm a target price of $300 per share in a positive scenario. Meanwhile, Meta Marshall from the same firm has set a target price of $1,150 per share for Axon in a similar optimistic outlook.